Virginia Athena Triant, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
HIV Infections | 57 | 2024 | 17352 | 3.180 |
Why?
|
Cardiovascular Diseases | 19 | 2024 | 15501 | 1.200 |
Why?
|
HIV | 10 | 2021 | 1582 | 1.160 |
Why?
|
Anti-HIV Agents | 11 | 2023 | 4527 | 0.960 |
Why?
|
Epidemics | 2 | 2021 | 512 | 0.770 |
Why?
|
Myocardial Infarction | 7 | 2024 | 11461 | 0.610 |
Why?
|
HIV Protease Inhibitors | 1 | 2020 | 432 | 0.580 |
Why?
|
Myocardial Ischemia | 2 | 2017 | 2113 | 0.540 |
Why?
|
Smoking Cessation | 2 | 2020 | 2057 | 0.540 |
Why?
|
CD4 Lymphocyte Count | 6 | 2019 | 2571 | 0.500 |
Why?
|
Stroke | 4 | 2020 | 9758 | 0.500 |
Why?
|
Behavior Therapy | 1 | 2020 | 879 | 0.470 |
Why?
|
Anti-Retroviral Agents | 5 | 2020 | 1784 | 0.460 |
Why?
|
Risk Factors | 35 | 2024 | 74213 | 0.460 |
Why?
|
Atherosclerosis | 3 | 2017 | 3408 | 0.420 |
Why?
|
Smoking | 4 | 2021 | 9053 | 0.420 |
Why?
|
Secondary Prevention | 1 | 2018 | 1475 | 0.400 |
Why?
|
Risk Reduction Behavior | 1 | 2018 | 1112 | 0.400 |
Why?
|
Cell Adhesion Molecules | 1 | 2018 | 1601 | 0.390 |
Why?
|
Carotid Artery Diseases | 4 | 2021 | 877 | 0.380 |
Why?
|
Patient Education as Topic | 1 | 2020 | 2319 | 0.340 |
Why?
|
Inflammation Mediators | 1 | 2018 | 1886 | 0.330 |
Why?
|
Coronary Disease | 2 | 2014 | 5914 | 0.310 |
Why?
|
Viral Load | 8 | 2019 | 3332 | 0.300 |
Why?
|
Brain Ischemia | 1 | 2020 | 3049 | 0.280 |
Why?
|
Risk Assessment | 11 | 2024 | 23996 | 0.280 |
Why?
|
Middle Aged | 44 | 2024 | 220920 | 0.270 |
Why?
|
Humans | 74 | 2024 | 761572 | 0.270 |
Why?
|
Antigens, Differentiation, Myelomonocytic | 2 | 2018 | 283 | 0.270 |
Why?
|
HIV Long-Term Survivors | 2 | 2019 | 121 | 0.260 |
Why?
|
Endothelium, Vascular | 1 | 2018 | 4431 | 0.260 |
Why?
|
Africa South of the Sahara | 2 | 2017 | 744 | 0.230 |
Why?
|
Adult | 31 | 2024 | 221203 | 0.230 |
Why?
|
Hospitalization | 5 | 2021 | 10721 | 0.220 |
Why?
|
Cerebral Hemorrhage | 1 | 2014 | 2656 | 0.210 |
Why?
|
Male | 41 | 2024 | 360842 | 0.210 |
Why?
|
Subacute Care | 2 | 2023 | 179 | 0.210 |
Why?
|
Female | 44 | 2024 | 392686 | 0.200 |
Why?
|
Botswana | 3 | 2023 | 1048 | 0.190 |
Why?
|
Data Interpretation, Statistical | 1 | 2011 | 2691 | 0.190 |
Why?
|
Skin Diseases, Viral | 1 | 2021 | 26 | 0.190 |
Why?
|
Mass Screening | 1 | 2017 | 5428 | 0.180 |
Why?
|
Incidence | 8 | 2021 | 21355 | 0.180 |
Why?
|
Death, Sudden, Cardiac | 2 | 2019 | 1555 | 0.180 |
Why?
|
Purpura | 1 | 2021 | 117 | 0.180 |
Why?
|
Boston | 4 | 2020 | 9326 | 0.170 |
Why?
|
Hepatitis C | 2 | 2022 | 1584 | 0.170 |
Why?
|
California | 1 | 2024 | 1430 | 0.170 |
Why?
|
Case Management | 1 | 2021 | 272 | 0.170 |
Why?
|
Systemic Inflammatory Response Syndrome | 2 | 2022 | 621 | 0.170 |
Why?
|
Pressure Ulcer | 1 | 2021 | 157 | 0.170 |
Why?
|
C-Reactive Protein | 2 | 2022 | 3826 | 0.170 |
Why?
|
Cohort Studies | 12 | 2021 | 41493 | 0.160 |
Why?
|
New York City | 1 | 2021 | 731 | 0.160 |
Why?
|
Heart Failure | 7 | 2020 | 11670 | 0.160 |
Why?
|
Microcirculation | 1 | 2023 | 1272 | 0.160 |
Why?
|
Inpatients | 2 | 2020 | 2548 | 0.160 |
Why?
|
Urban Health | 1 | 2021 | 532 | 0.160 |
Why?
|
Antigens, CD | 3 | 2018 | 4001 | 0.160 |
Why?
|
Antiretroviral Therapy, Highly Active | 2 | 2018 | 1897 | 0.160 |
Why?
|
Patient Discharge | 2 | 2023 | 3443 | 0.150 |
Why?
|
Receptors, Cell Surface | 2 | 2018 | 2822 | 0.150 |
Why?
|
Sex Factors | 3 | 2024 | 10553 | 0.150 |
Why?
|
Case-Control Studies | 6 | 2023 | 22176 | 0.140 |
Why?
|
Decision Support Techniques | 2 | 2018 | 1998 | 0.140 |
Why?
|
Aged | 23 | 2023 | 169310 | 0.140 |
Why?
|
Myocardium | 2 | 2020 | 4725 | 0.140 |
Why?
|
Adipose Tissue | 2 | 2020 | 3312 | 0.140 |
Why?
|
Exanthema | 1 | 2021 | 503 | 0.140 |
Why?
|
Viral Nonstructural Proteins | 1 | 2018 | 227 | 0.130 |
Why?
|
Fractures, Bone | 1 | 2008 | 2046 | 0.130 |
Why?
|
Accidental Falls | 1 | 2024 | 1068 | 0.130 |
Why?
|
Uganda | 5 | 2021 | 1332 | 0.130 |
Why?
|
E-Selectin | 1 | 2018 | 576 | 0.130 |
Why?
|
Hormones | 1 | 2019 | 869 | 0.130 |
Why?
|
Vascular Cell Adhesion Molecule-1 | 1 | 2018 | 691 | 0.130 |
Why?
|
Obesity | 5 | 2022 | 12947 | 0.130 |
Why?
|
Nitrates | 1 | 2016 | 263 | 0.120 |
Why?
|
Risk | 2 | 2017 | 9610 | 0.120 |
Why?
|
Hepacivirus | 2 | 2022 | 1336 | 0.120 |
Why?
|
Disease Management | 2 | 2017 | 2508 | 0.120 |
Why?
|
Protease Inhibitors | 1 | 2018 | 754 | 0.120 |
Why?
|
Continuity of Patient Care | 1 | 2021 | 1069 | 0.120 |
Why?
|
Prevalence | 6 | 2023 | 15732 | 0.120 |
Why?
|
Intercellular Adhesion Molecule-1 | 1 | 2018 | 1126 | 0.120 |
Why?
|
Arteritis | 1 | 2016 | 158 | 0.120 |
Why?
|
Aftercare | 1 | 2020 | 914 | 0.110 |
Why?
|
Risk Management | 1 | 2017 | 558 | 0.110 |
Why?
|
Coronary Artery Disease | 4 | 2020 | 6403 | 0.110 |
Why?
|
Monocytes | 2 | 2020 | 2570 | 0.110 |
Why?
|
United States | 10 | 2022 | 72335 | 0.110 |
Why?
|
Pericardium | 1 | 2018 | 675 | 0.110 |
Why?
|
Patient Readmission | 4 | 2023 | 3271 | 0.110 |
Why?
|
Fibrosis | 1 | 2020 | 2049 | 0.100 |
Why?
|
Drug Resistance, Viral | 1 | 2018 | 862 | 0.100 |
Why?
|
Time Factors | 4 | 2021 | 39970 | 0.100 |
Why?
|
American Heart Association | 1 | 2017 | 1039 | 0.100 |
Why?
|
Interleukin-6 | 2 | 2022 | 3208 | 0.100 |
Why?
|
Buprenorphine | 1 | 2020 | 656 | 0.100 |
Why?
|
Drug Interactions | 1 | 2016 | 1416 | 0.100 |
Why?
|
Diazepam | 1 | 2013 | 215 | 0.100 |
Why?
|
Preventive Health Services | 1 | 2017 | 567 | 0.100 |
Why?
|
Triglycerides | 1 | 2019 | 2461 | 0.100 |
Why?
|
Hyperlipidemias | 1 | 2017 | 771 | 0.100 |
Why?
|
Hypertension | 3 | 2023 | 8540 | 0.100 |
Why?
|
Inflammation | 3 | 2016 | 10773 | 0.100 |
Why?
|
Longitudinal Studies | 4 | 2021 | 14607 | 0.100 |
Why?
|
Comorbidity | 4 | 2020 | 10508 | 0.090 |
Why?
|
Cholesterol, HDL | 1 | 2018 | 1814 | 0.090 |
Why?
|
Midazolam | 1 | 2013 | 266 | 0.090 |
Why?
|
Cardiomyopathies | 2 | 2020 | 1964 | 0.090 |
Why?
|
Length of Stay | 2 | 2023 | 6426 | 0.090 |
Why?
|
Prognosis | 3 | 2024 | 29629 | 0.090 |
Why?
|
Diabetic Angiopathies | 1 | 2015 | 803 | 0.090 |
Why?
|
Retrospective Studies | 12 | 2023 | 80646 | 0.090 |
Why?
|
Cross-Sectional Studies | 4 | 2023 | 26127 | 0.090 |
Why?
|
Tobacco Use Disorder | 1 | 2016 | 703 | 0.090 |
Why?
|
Sleep Apnea Syndromes | 1 | 2018 | 975 | 0.090 |
Why?
|
Aging | 4 | 2022 | 8711 | 0.090 |
Why?
|
Angiotensin-Converting Enzyme Inhibitors | 1 | 2016 | 1516 | 0.080 |
Why?
|
Heart | 2 | 2020 | 4404 | 0.080 |
Why?
|
Anesthetics, Intravenous | 1 | 2013 | 395 | 0.080 |
Why?
|
Aged, 80 and over | 8 | 2024 | 58986 | 0.080 |
Why?
|
Antiviral Agents | 2 | 2022 | 3060 | 0.080 |
Why?
|
Anticholesteremic Agents | 1 | 2016 | 966 | 0.080 |
Why?
|
Vaccination | 1 | 2021 | 3384 | 0.080 |
Why?
|
International Classification of Diseases | 1 | 2014 | 909 | 0.080 |
Why?
|
Delivery of Health Care | 4 | 2022 | 5336 | 0.080 |
Why?
|
Dementia | 1 | 2023 | 2689 | 0.080 |
Why?
|
Hypoglycemia | 1 | 2015 | 883 | 0.080 |
Why?
|
Communicable Diseases | 1 | 2017 | 875 | 0.080 |
Why?
|
Plaque, Atherosclerotic | 1 | 2020 | 1533 | 0.080 |
Why?
|
Regression Analysis | 1 | 2018 | 6344 | 0.080 |
Why?
|
Acquired Immunodeficiency Syndrome | 1 | 2017 | 2199 | 0.070 |
Why?
|
Diabetes Mellitus | 2 | 2017 | 5841 | 0.070 |
Why?
|
Emigrants and Immigrants | 1 | 2014 | 543 | 0.070 |
Why?
|
Ventricular Dysfunction, Left | 1 | 2018 | 2118 | 0.070 |
Why?
|
Medical Informatics | 1 | 2014 | 733 | 0.070 |
Why?
|
Intensive Care Units | 1 | 2020 | 3744 | 0.070 |
Why?
|
Blood Pressure | 2 | 2023 | 8481 | 0.070 |
Why?
|
Pulmonary Disease, Chronic Obstructive | 1 | 2021 | 3204 | 0.070 |
Why?
|
HIV-1 | 3 | 2019 | 6863 | 0.070 |
Why?
|
Linear Models | 1 | 2016 | 5872 | 0.060 |
Why?
|
Socioeconomic Factors | 2 | 2017 | 7827 | 0.060 |
Why?
|
Young Adult | 5 | 2018 | 59255 | 0.060 |
Why?
|
Adolescent | 5 | 2018 | 88324 | 0.060 |
Why?
|
Opioid-Related Disorders | 1 | 2020 | 2164 | 0.060 |
Why?
|
Colonoscopy | 1 | 2013 | 1394 | 0.060 |
Why?
|
Platelet Aggregation Inhibitors | 1 | 2016 | 2751 | 0.060 |
Why?
|
Uterine Cervical Neoplasms | 1 | 2017 | 2020 | 0.060 |
Why?
|
Treatment Outcome | 5 | 2022 | 64684 | 0.060 |
Why?
|
Calcinosis | 1 | 2012 | 1469 | 0.060 |
Why?
|
Pilot Projects | 1 | 2017 | 8633 | 0.050 |
Why?
|
Dideoxynucleosides | 1 | 2023 | 135 | 0.050 |
Why?
|
Databases, Factual | 1 | 2018 | 7967 | 0.050 |
Why?
|
Coronavirus Infections | 1 | 2020 | 3086 | 0.050 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 3206 | 0.050 |
Why?
|
Lamivudine | 1 | 2023 | 366 | 0.050 |
Why?
|
Lymphocyte Activation | 1 | 2012 | 5485 | 0.050 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2016 | 3245 | 0.050 |
Why?
|
Asthma | 1 | 2020 | 6234 | 0.050 |
Why?
|
Electronic Health Records | 2 | 2020 | 4811 | 0.050 |
Why?
|
Predictive Value of Tests | 1 | 2018 | 15266 | 0.050 |
Why?
|
Oxazines | 1 | 2023 | 350 | 0.050 |
Why?
|
Age Distribution | 1 | 2007 | 2880 | 0.050 |
Why?
|
Anticoagulants | 1 | 2016 | 4812 | 0.050 |
Why?
|
Blood Sedimentation | 1 | 2022 | 235 | 0.050 |
Why?
|
Alanine | 1 | 2023 | 609 | 0.050 |
Why?
|
Drug Substitution | 1 | 2023 | 290 | 0.050 |
Why?
|
Heterocyclic Compounds, 3-Ring | 1 | 2023 | 287 | 0.050 |
Why?
|
Logistic Models | 2 | 2020 | 13255 | 0.050 |
Why?
|
Prone Position | 1 | 2021 | 196 | 0.040 |
Why?
|
Proportional Hazards Models | 1 | 2014 | 12463 | 0.040 |
Why?
|
Government Programs | 1 | 2022 | 279 | 0.040 |
Why?
|
Fibrin Fibrinogen Degradation Products | 1 | 2022 | 422 | 0.040 |
Why?
|
Hospitals, Urban | 1 | 2021 | 500 | 0.040 |
Why?
|
Ferritins | 1 | 2022 | 598 | 0.040 |
Why?
|
Chronic Disease | 1 | 2014 | 9319 | 0.040 |
Why?
|
Acute Disease | 1 | 2009 | 7237 | 0.040 |
Why?
|
Myocardial Perfusion Imaging | 1 | 2023 | 575 | 0.040 |
Why?
|
Pyridones | 1 | 2023 | 809 | 0.040 |
Why?
|
Cause of Death | 2 | 2019 | 3683 | 0.040 |
Why?
|
Leukocyte Count | 1 | 2022 | 1596 | 0.040 |
Why?
|
Age Factors | 1 | 2014 | 18398 | 0.040 |
Why?
|
Coronary Circulation | 1 | 2023 | 1569 | 0.040 |
Why?
|
Drug Combinations | 1 | 2023 | 2048 | 0.040 |
Why?
|
Gene Expression Regulation | 1 | 2015 | 11904 | 0.040 |
Why?
|
Models, Statistical | 1 | 2011 | 5079 | 0.030 |
Why?
|
Colorectal Neoplasms | 1 | 2017 | 6935 | 0.030 |
Why?
|
Registries | 2 | 2014 | 8224 | 0.030 |
Why?
|
Health Facilities | 1 | 2021 | 580 | 0.030 |
Why?
|
Causality | 1 | 2022 | 1242 | 0.030 |
Why?
|
Hospitals, General | 1 | 2020 | 798 | 0.030 |
Why?
|
Diabetes Mellitus, Type 2 | 1 | 2020 | 12148 | 0.030 |
Why?
|
Gastrointestinal Tract | 1 | 2022 | 833 | 0.030 |
Why?
|
Multivariate Analysis | 1 | 2009 | 12059 | 0.030 |
Why?
|
Opiate Substitution Treatment | 1 | 2020 | 444 | 0.030 |
Why?
|
Research Design | 1 | 2011 | 6180 | 0.030 |
Why?
|
Cocaine-Related Disorders | 1 | 2019 | 461 | 0.030 |
Why?
|
Feces | 1 | 2022 | 1497 | 0.030 |
Why?
|
Models, Biological | 1 | 2011 | 9469 | 0.030 |
Why?
|
Stroke Volume | 2 | 2019 | 5496 | 0.030 |
Why?
|
Biostatistics | 1 | 2016 | 164 | 0.030 |
Why?
|
Asymptomatic Diseases | 1 | 2018 | 588 | 0.030 |
Why?
|
Cognition | 2 | 2023 | 6992 | 0.030 |
Why?
|
Carotid Arteries | 1 | 2018 | 941 | 0.030 |
Why?
|
Algorithms | 1 | 2014 | 14032 | 0.030 |
Why?
|
RNA, Viral | 1 | 2022 | 2846 | 0.030 |
Why?
|
Piperazines | 1 | 2023 | 2523 | 0.030 |
Why?
|
Intubation, Intratracheal | 1 | 2021 | 1333 | 0.030 |
Why?
|
RNA | 1 | 2023 | 2726 | 0.030 |
Why?
|
Coronary Vessels | 1 | 2023 | 3096 | 0.020 |
Why?
|
Sensitivity and Specificity | 1 | 2007 | 14666 | 0.020 |
Why?
|
Treatment Failure | 1 | 2018 | 2644 | 0.020 |
Why?
|
Disease Susceptibility | 1 | 2018 | 1787 | 0.020 |
Why?
|
Cost of Illness | 1 | 2020 | 1936 | 0.020 |
Why?
|
Reference Standards | 1 | 2014 | 1003 | 0.020 |
Why?
|
Disease Progression | 2 | 2021 | 13510 | 0.020 |
Why?
|
Academic Medical Centers | 1 | 2021 | 2759 | 0.020 |
Why?
|
Magnetic Resonance Spectroscopy | 1 | 2019 | 3769 | 0.020 |
Why?
|
Breast Neoplasms | 1 | 2017 | 21017 | 0.020 |
Why?
|
DNA Mutational Analysis | 1 | 2018 | 4111 | 0.020 |
Why?
|
Data Mining | 1 | 2014 | 551 | 0.020 |
Why?
|
Respiration, Artificial | 1 | 2020 | 2630 | 0.020 |
Why?
|
Defibrillators, Implantable | 1 | 2018 | 1490 | 0.020 |
Why?
|
Reproducibility of Results | 1 | 2007 | 20099 | 0.020 |
Why?
|
Body Composition | 1 | 2018 | 2426 | 0.020 |
Why?
|
Dyslipidemias | 1 | 2015 | 868 | 0.020 |
Why?
|
Odds Ratio | 1 | 2020 | 9646 | 0.020 |
Why?
|
Patient Acceptance of Health Care | 1 | 2021 | 3205 | 0.020 |
Why?
|
Drug Therapy, Combination | 1 | 2018 | 6312 | 0.020 |
Why?
|
Massachusetts | 1 | 2020 | 8830 | 0.020 |
Why?
|
Angiography | 1 | 2012 | 1595 | 0.020 |
Why?
|
Positron-Emission Tomography | 1 | 2023 | 6485 | 0.020 |
Why?
|
Mortality | 1 | 2018 | 2901 | 0.020 |
Why?
|
Ventricular Function, Left | 1 | 2019 | 3879 | 0.020 |
Why?
|
Hospital Mortality | 1 | 2020 | 5293 | 0.020 |
Why?
|
Prospective Studies | 2 | 2021 | 54426 | 0.020 |
Why?
|
Rural Population | 1 | 2016 | 2285 | 0.020 |
Why?
|
Language | 1 | 2014 | 1540 | 0.010 |
Why?
|
Analgesics, Opioid | 1 | 2020 | 3808 | 0.010 |
Why?
|
Genotype | 1 | 2018 | 12990 | 0.010 |
Why?
|
Severity of Illness Index | 1 | 2020 | 15843 | 0.010 |
Why?
|
Magnetic Resonance Imaging | 2 | 2020 | 36429 | 0.010 |
Why?
|
Pandemics | 1 | 2020 | 8656 | 0.010 |
Why?
|
Cytokines | 1 | 2015 | 7396 | 0.010 |
Why?
|
Infant | 1 | 2022 | 36192 | 0.010 |
Why?
|
Primary Health Care | 1 | 2015 | 4686 | 0.010 |
Why?
|
Follow-Up Studies | 1 | 2018 | 39107 | 0.010 |
Why?
|
Tomography, X-Ray Computed | 1 | 2018 | 20571 | 0.010 |
Why?
|